There are currently 47 active clinical trials seeking participants for Prostate Adenocarcinoma research studies. The states with the highest number of trials for Autism participants are Illinois, California, Pennsylvania and Wisconsin.
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
NCT06235099
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Tower Urology, Los Angeles, California +10 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
Register for Updates
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Tower Urology, Los Angeles, California +8 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
NCT06369610
Recruiting
This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Zytiga), lower the amount of the male hormone, testosterone, made by the body. This may help kill or stop the growth of tumor cells that need testosterone to grow. Radiation therapy uses high energy x-rays, particles, or... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen [PSA] after surgical removal of the pros... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +291 locations
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
NCT05832086
Recruiting
This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet. All patients will receive standard of care treatment for their prostate cancer. The fasting mimicking diet will be consumed for 5 days per month for a total of 6 months and will be monitored by trained research dietitians. This study aims to examine the effects of a fasting mimi... Read More
Gender:
Male
Ages:
All
Trial Updated:
04/13/2024
Locations: Beckman Research Institute of the City of Hope, Duarte, California +2 locations
Conditions: Prostate Adenocarcinoma
Register for Updates
A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
NCT05027477
Recruiting
Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial. This study will determine whether the TULSA procedure is as effective and more safe compared to radical prostatectomy.
Gender:
Male
Ages:
Between 40 years and 80 years
Trial Updated:
04/08/2024
Locations: East Valley Urological Center, Mesa, Arizona +16 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT05726292
Recruiting
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
NCT05960578
Recruiting
This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2024
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +132 locations
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
NCT04030338
Recruiting
The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Metastatic Prostate Cancer
Register for Updates
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
NCT04870515
Recruiting
This clinical trial studies the effects of a diet and physical activity intervention on blood measures of lipids and insulin resistance in patients with prostate cancer undergoing radiation therapy (RT) and androgen deprivation therapy (ADT). ADT effectively slows the growth of prostate cancer cells, thereby enhancing the therapeutic effectiveness of RT. Despite the clinical gains, ADT leads to an array of side effects including insulin resistance, abnormal lipid levels, weight gain, increased v... Read More
Gender:
Male
Ages:
40 years and above
Trial Updated:
03/27/2024
Locations: Veterans Affairs Puget Sound Health Care System, Seattle, Washington +1 locations
Conditions: Localized Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
NCT04300855
Recruiting
This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D) containing 405 mgs vs. Placebo, administered for 24 months in a cohort of men with low to intermediate grade prostate managed on active surveillance
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates